Inotiv (Inotiv) Total Liabilities : $581.3 Mil (As of Dec. 2023)

View and export this data going back to 1997. Start your Free Trial

What is Inotiv Total Liabilities?

Inotiv's Total Liabilities for the quarter that ended in Dec. 2023 was $581.3 Mil.

Inotiv's quarterly Total Liabilities increased from Jun. 2023 ($579.50 Mil) to Sep. 2023 ($588.04 Mil) but then declined from Sep. 2023 ($588.04 Mil) to Dec. 2023 ($581.35 Mil).

Inotiv's annual Total Liabilities increased from Sep. 2021 ($216.73 Mil) to Sep. 2022 ($603.13 Mil) but then declined from Sep. 2022 ($603.13 Mil) to Sep. 2023 ($588.04 Mil).

Inotiv Total Liabilities Historical Data

The historical data trend for Inotiv's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Inotiv Total Liabilities Chart

Inotiv Annual Data

Trend

Sep14

Sep15

Sep16

Sep17

Sep18

Sep19

Sep20

Sep21

Sep22

Sep23

Total Liabilities

Get a 7-Day Free Trial

31.27

54.00

216.73

603.13

588.04

Inotiv Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Total Liabilities	Get a 7-Day Free Trial															591.25	596.03	579.50	588.04	581.35

Inotiv Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Inotiv's Total Liabilities for the fiscal year that ended in Sep. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	132.194	+	(399.409	+	6.373
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	50.064	+	0)
	=	588.0

Total Liabilities	=	Total Assets (A: Sep. 2023 )	-	Total Equity (A: Sep. 2023 )
	=	856.53	-	268.49
	=	588.0

Inotiv's Total Liabilities for the quarter that ended in Dec. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	109.489	+	(409.005	+	0.96699999999993
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	61.887	+	0)
	=	581.3

Total Liabilities	=	Total Assets (Q: Dec. 2023 )	-	Total Equity (Q: Dec. 2023 )
	=	835.51	-	254.162
	=	581.3

Inotiv Total Liabilities Related Terms

Thank you for viewing the detailed overview of Inotiv's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Inotiv (Inotiv) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Inotiv Inc (NAS:NOTV) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

BS50:Germany

Address

2701 Kent Avenue, West Lafayette, IN, USA, 47906

Website

https://www.inotivco.com

Inotiv Inc is a pharmaceutical development company specializing in nonclinical and analytical drug discovery and development services to the pharmaceutical, chemical, and medical device industries. It operates in two segments; Discovery and Safety Assessment (DSA) and Research Models and Services (RMS). Through the DSA segment, it supports the discovery, nonclinical development, and clinical development needs of researchers and clinicians for small molecule drug candidates, as well as biotherapeutics and biomedical devices. Through the RMS segment, it offers access to a wide range of small and large research models for basic research and drug discovery and development, as well as specialized models for specific diseases and therapeutic areas. It earns maximum revenue from RMS Segment.

Executives

John Gregory Beattie	officer: Chief Operating Officer	C/O BIOANALYTICAL SYSTEMS, INC., 2701 KENT AVENUE, WEST LAFAYETTE IN 47906
Michael Garrett	officer: Chief Commercial Officer	250 PEHLE DRIVE, SUITE 601, SADDLE BROOK NJ 07663
Andrea Castetter	officer: SVP, Gen. Counsel & Secretary	2701 KENT AVENUE, WEST LAFAYETTE IN 47906-1382
Mary Theresa Coelho	director	52 SUNRISE PARK ROAD, NEW HAMPTON NY 43017
John E Sagartz	director, officer: Chief Strategy Officer	19 WORTHINGTON ACCESS DRIVE, MARYLAND HEIGHTS MO 63043
David Landman	director	2701 KENT AVENUE, WEST LAFAYETTE IN 47906-1382
Robert Jr. Leasure	director, officer: President and CEO	C/O BIOANALYTICAL SYSTEMS, INC., 2701 KENT AVENUE, WEST LAFAYETTE IN 47906-1382
Beth Taylor	officer: Chief Financial Officer	3000 KENT AVENUE, SUITE A1-100, WEST LAFAYETTE IN 47906
Jeffrey Arthur Krupp	officer: Chief Human Resources Officer	2701 KENT AVENUE, WEST LAFAYETTE IN 47906-1382
William D Pitchford	officer: Chief Human Resources Officer	1000 SAGAMORE PARKWAY SOUTH, LAFAYETTE IN 47905
R Matthew Neff	director	535 N. COLLEGE DRIVE, CARMEL IN 46032
Jeffrey Brennan Freeman	officer: VP-Finance & Corp. Controller	2701 KENT AVENUE, WEST LAFAYETTE IN 47906-1382
Davis Gregory Cole	director	C/O BIOANALYTICAL SYSTEMS, INC., 2701 KENT AVENUE, WEST LAFAYETTE IN 47906
Nigel Brown	director	250 PEHLE AVENUE, SUITE 600, SADDLE BROOK NJ 07663
Scott Cragg	director	660 MADISON AVENUE, NEW YORK NY 10065